Introduction
============

Patients with *EGFR*-mutant non-small-cell lung cancer (NSCLC) derive great benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs) but the response is often not long-lasting. Exploring resistance mechanisms has been an area of hot pursuit. In addition to the most common EGFR T790M mutation, other mechanisms of acquired resistance include *MET* amplification (5%--20%), *HER2* amplification (5%--13%), *EGFR* amplification (8%), *BRAF* mutations (1%), and so on.[@b1-lctt-10-021] Crizotinib, a small molecule TKI against ALK, ROS1, and MET, has recently been granted a breakthrough therapy designation by the US Food and Drug Administration for patients with metastatic NSCLC harboring *MET* exon 14 skipping alterations after platinum-based chemotherapy. For patients with *MET*-amplified NSCLC, as well as other tumor types, crizotinib has also been reported to be an effective therapy, demonstrating that *MET* amplification is indeed an actionable genomic alteration. Here we report a case of emergent *MET* amplification detected in a tumor sample from a patient with NSCLC harboring EGFR L858R mutation after disease progression on erlotinib. The patient subsequently had a sustained partial response (PR) to a combination of full-dose osimertinib and crizotinib with excellent tolerance but eventually had central nervous system (CNS) progression highlighting the need to develop next-generation MET inhibitors with better CNS activity.

Case presentation
=================

This is a 55-year-old African--American male never-smoker who was diagnosed with stage IV NSCLC in December 2016 after presenting with self-palpable lymph node in the neck. His disease burden involved a dominant right apex lung mass, bilateral lung nodules, extensive lymphadenopathy, multiple liver lesions, one single bony lesion in the T6 vertebral body, and two brain lesions. He first received one cycle of carboplatin/nab-paclitaxel in January 2017. When comprehensive genomic profiling (CGP) on his lymph node biopsy specimen revealed EGFR L858R mutation and equivocal *EGFR* amplification (7 copies) by Foundation Medicine (Cambridge, MA, USA), his treatment was switched to erlotinib in early February 2017 ([Table 1](#t1-lctt-10-021){ref-type="table"}). In the interim, he also received stereotactic radiation to two brain lesions. The patient had a PR to erlotinib, but in July 2017 was found to have a new brain lesion for which he received additional stereotactic radiation while being continued on erlotinib. His scan in September 2017 was concerning for mild disease progression so liquid biopsy was obtained via Guardant360 (Guardant Health, Redwood City, CA, USA) which showed EGFR L858R without T790M mutation. A follow-up scan in November 2017 confirmed disease progression in his lung and liver. He then underwent biopsy of a liver mass and CGP revealed EGFR L858R, *EGFR* amplification (17 copies), *MET* amplification (12 copies), among other non-actionable genomic alterations ([Table 1](#t1-lctt-10-021){ref-type="table"}; [Figure 1](#f1-lctt-10-021){ref-type="fig"}).

The patient subsequently transferred care to us. He had successful microwave ablation of a hepatic lesion at the end of January 2018. For his systemic treatment, erlotinib was switched to a combination of osimertinib and crizotinib in early February 2018 in an attempt to target both *EGFR* and *MET* alterations. We started the patient on 80 mg daily osimertinib and 250 mg daily crizotinib with close monitoring for toxicity. The main reason to choose osimertinib over erlotinib in the absence of T790M mutation is better tolerability of osimertinib particularly when it is combined with another TKI. Ten days later, crizotinib dose was titrated up to 250 mg twice daily given excellent tolerance. Restaging scans around 8 weeks showed interval significant decrease in size of the right apex lung mass and slight decrease in size of a hepatic mass. He had a sustained PR as follow-up scans \~20 weeks later showed further improvement of target lesions (−32% by RECIST 1.1) ([Figure 2A--I](#f2-lctt-10-021){ref-type="fig"}). However, despite good extracranial response after 28 weeks of combination therapy, the patient experienced CNS progression with increase in size of a pre-existing lesion ([Figure 2J and K](#f2-lctt-10-021){ref-type="fig"}) and development of three new punctate lesions. He underwent resection of the enlarging brain metastasis ([Figure 2L](#f2-lctt-10-021){ref-type="fig"}) and CGP performed on this tumor specimen again identified EGFR L858R, *EGFR* amplification (42 copies), and *MET* amplification (35 copies) without revealing additional mechanisms of resistance ([Table 1](#t1-lctt-10-021){ref-type="table"}). Following resection, the patient received stereotactic radiation to the surgical bed and other untreated brain lesions. He remained on full-dose osimertinib and crizotinib without any toxicity. At the time of this manuscript submission, his combination therapy has been ongoing for 35 weeks. The schematic summary of treatment course is shown in [Figure 3](#f3-lctt-10-021){ref-type="fig"}. The patient has provided a written informed consent to have the case details published, and institutional approval is not required to publish this case report.

Discussion
==========

*MET* amplification has been well documented to confer acquired resistance in patients with *EGFR*-mutant NSCLC after progression on various EGFR TKIs. Crizotinib has known activity against *MET* amplification. In fact, we have previously reported a case of high *MET* amplification (30 copies) in a patient who progressed on osimertinib and then responded to crizotinib symptomatically.[@b2-lctt-10-021] Other agents, such as cabozantinib, capmatinib, emibetuzumab, glesatinib, merestinib, telisotuzumab vedotin, tepotinib, and savolitinib, can also target *MET* amplification. It is worth mentioning that the cutoff for *MET* amplification varies by detection method. Using fluorescent in situ hybridization, a *MET*/*CEP7* (centromeric enumeration probe for chromosome 7) ratio ≥2 defines high-level amplification, whereas CGP reports gene copy number per cell ≥6 as amplification.[@b3-lctt-10-021] We have previously investigated focal (\<20 megabase pair) vs non-focal *MET* amplification in 545 NSCLC cases and found that focal *MET* amplification was associated with higher *MET* copy number (median 11 vs 7 copies) and lower co-occurrence of other driver mutations.[@b4-lctt-10-021] Whether or not this can serve as a prognostic or predictive biomarker for patients receiving anti-MET targeted therapies has yet to be elucidated.

The use of combination TKI therapy to dual-target primary and resistance genomic alterations when patients progress on targeted therapies is emerging in clinical practice. For instance, Scheffler et al successfully treated an NSCLC patient with erlotinib at 100 mg daily in combination with crizotinib at 250 mg twice daily when rebiopsy showed high-level *MET* amplification (*MET*/*CEP7* ratio: 8.3) emerging in the setting of EGFR L858R mutation. The patient had a dramatic response to this combination therapy.[@b5-lctt-10-021] Gainor et al reported a NSCLC case with EGFR L858R mutation and de novo high-level *MET* amplification (*MET*/*CEP7* ratio: \>15) that was primarily resistant to erlotinib but had an excellent response to the combination of erlotinib at 100 mg daily and crizotinib at 250 mg daily. The lower than standard doses were chosen given concern for increased exposure of erlotinib by crizotinib, and this patient tolerated the treatment well with only grade 1 rash and diarrhea.[@b6-lctt-10-021] Li et al also used the same combination therapy to target pre-existing EGFR L858R mutation and secondary *MET* amplification in a patient who had progressed on erlotinib. While this patient also had an excellent response, the combination erlotinib at 150 mg daily and crizotinib at 250 mg daily resulted in severe vomiting and rash.[@b7-lctt-10-021] Osimertinib is now moving to the front-line setting for metastatic NSCLC patients with activating *EGFR* mutations based on the FLAURA trial showing its superior efficacy and tolerability (lower rates of serious adverse events) to gefitinib or erlotinib. The combination of osimertinib and MET inhibitors has proven to be safe and efficacious. This was first demonstrated by York et al in the management of an African American NSCLC patient with emergent *MET* amplification (*MET*/*CEP7* ratio: 3.67) after EGFR T790M mutation. The patient received 80 mg daily osimertinib and 200 mg twice daily crizotinib at first with repeat scans after four months of therapy showing significant improvement. Notably, when serum carcinoembryonic antigen (CEA) started to rise, the dose of crizotinib was increased to 250 mg twice daily resulting in reduction of the CEA level. The most notable toxicity was grade 2 fatigue.[@b8-lctt-10-021] Kang et al reported a case of acquired *MET* amplification with pre-existing EGFR L858R and T790M mutations that achieved a PR to full-dose osimertinib and crizotinib after becoming resistant to gefitinib and then osimertinib. This patient subsequently developed multiple *MET* secondary-site mutations and responded symptomatically when crizotinib was switched to cabozantinib at 80 mg daily.[@b9-lctt-10-021] Most recently, Deng et al treated a Hispanic male patient with a combination of osimertinib at 80 mg daily and crizotinib at 250 mg daily in the setting of severe hepatic dysfunction when liquid biopsy revealed *MET* amplification (5.3 copies) in addition to three pre-existing EGFR mutations including EGFR L858R, R776C, and T790M. The dose of crizotinib had to be reduced to 200 mg daily due to grade 3 neutropenia, nausea, and lower extremity edema. This combination therapy had provided clinical benefit for 6 months until the patient experienced disease progression with rising *MET* copy number to 22.4 copies.[@b10-lctt-10-021]

While our patient derived good extrancranial response to full-dose osimertinib and crizotinib without experiencing any toxicity, he eventually progressed in the brain 28 weeks into combination therapy. Interestingly, CGP performed on the resected brain specimen did not reveal additional resistance mechanisms suggesting *MET* amplification likely continued to contribute to acquired resistance. This is not entirely surprising as crizotinib, a type Ia MET inhibitor, is well known to have poor brain penetration. Switching to a different MET inhibitor with potentially better CNS activity, such as cabozantinib, a type II MET inhibitor, can be considered should the patient develop further CNS progression.[@b11-lctt-10-021],[@b12-lctt-10-021]

Conclusion
==========

As more actionable resistance mechanisms are identified in *EGFR*-mutant NSCLC patients, we envision combination TKI therapy will be readily adopted in clinical practice. Understanding the safety profile of each agent and drug interactions will be essential to provide effective yet tolerable combination therapy. Notably, we have successfully treated a patient with full-dose osimertinib and alectinib when liquid biopsy detected a novel in-frame *PLEKHA7-ALK* fusion after the patient had developed resistance to sequential erlotinib, afatinib, and osimertinib.[@b13-lctt-10-021] Taken together, our case report adds to a growing body of evidence that combination of osimertinib and crizotinib should be recommended to *EGFR*-mutant NSCLC patients with emergent *MET* amplification as acquired resistance. More importantly, developing next-generation MET inhibitors with better CNS activity is urgently needed.
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![Copy number plot for the liver biopsy sample tested before combination therapy of osimertinib and crizotinib.\
**Notes:** The x-axis shows the target positions (exons); the left y-axis, the log ratio; the right y-axis, gene copy number. Vertical lines indicate divisions between chromosomes (numbered at the lower left corner of each section).](lctt-10-021Fig1){#f1-lctt-10-021}

![CT images showing the right apex lung mass before (**A** & **D**), 8 weeks after (**B** & **E**), and 28 weeks after (**C** & **F**) combination therapy of osimertinib and crizotinib. The red arrows indicate the right apex lung mass seen on the axial view (**A**--**C**) as well as the coronal view (**D**--**F**). CT images showing a hepatic mass before (**G**), 8 weeks after (**H**), and 28 weeks after (**I**) combination therapy of osimertinib and crizotinib. This patient also received microwave ablation of this hepatic mass prior to initiation of the combination therapy. MRI images showing the posterior left temporal lobe mass 18 weeks after (**J**) and 28 weeks after (**K**) combination therapy of osimertinib and crizotinib. The red circles clearly indicate disease progression at 28 weeks as demonstrated by the interval increase in size of the mass. Of note, this mass had previously received stereotactic radiation. The patient subsequently underwent total resection of the mass (**L**).](lctt-10-021Fig2){#f2-lctt-10-021}

![Schematic summary of treatment course.\
**Abbreviations:** CGP, comprehensive genomic profiling; CNS, central nervous system; LN, lymph node; PD, progressive disease; SRS, stereotactic radiosurgery.](lctt-10-021Fig3){#f3-lctt-10-021}

###### 

List of genomic alterations detected from three different metastatic sites over the clinical course

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Timing                 Initial diagnosi                               Pre-combination therapy               28 Weeks after combination therapy
  ---------------------- ---------------------------------------------- ------------------------------------- ------------------------------------
  Specimen site          Lymph node                                     Liver                                 Brain

  Driver mutations       EGFR L858R\                                    EGFR L858R\                           EGFR L858R\
                         *EGFR* amplification -- equivocal (7 copies)   *EGFR* amplification (17 copies)\     *EGFR* amplification (42 copies)\
                                                                        *MET* amplification (12 copies)       *MET* amplification (35 copies)

  Associated mutations   *CCNE1* amplification -- equivocal             *CDK6* amplification\                 *CDK6* amplification\
                                                                        *MYC* amplification -- equivocal\     *MYC* amplification\
                                                                        *CCNE1* amplification\                *CCNE1* amplification\
                                                                        *NFKBIA* amplification -- equivocal   *IRS2* amplification\
                                                                                                              *NFKBIA* amplification\
                                                                                                              *NKX2-1* amplification\
                                                                                                              *RAD21* amplification

  MSI                    N/A                                            Stable                                Stable

  TMB (Muts/Mb)          3 (low)                                        4 (low)                               10 (intermediate)
  ------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** MSI, microsatellite instability**;** Muts/Mb, mutations per megabase; N/A, not available; TMB, tumor mutational burden.
